In the setting of renal transplantation, a prospective randomized study has reported that patients receiving tacrolimus (FK) instead of cyclosporine A (CsA) as part of the antirejection prophylaxis were at increased risk of developing BKV viremia and thus PV-associated nephropathy. 4 The aim of the present study was to investigate whether the type of calcineurin inhibitor (CNI) used as part of GVHD prophylaxis, FK or CsA impacted on the development of PV-HC in a population of patients undergoing HLA-haploidentical (haplo) HSCT for hematological malignancies.
This was a retrospective study conducted on 161 consecutive adult patients who received a T cell-replete haplo HSCT with post-transplant cyclophosphamide (PT-Cy) for malignant disorders between April 2009 and April 2014. Transplants were performed at two centers: Humanitas Clinical and Research Center (Rozzano, Italy) and Institut Paoli Calmettes (Marseille, France). All patients received unmanipulated bone marrow or PBSCs on day 0. GVHD prophylaxis consisted of the administration of Cy 50 mg/kg/day IV on days +3 and +4; FK 1 mg/day IV from day +5 (to reach a concentration of 10-20 ng/mL) or CsA 3 mg/kg/day IV from day +5 (to reach a concentration of 100-200 ng/mL), both drugs up to day +100 and then tapered between days +100 and +180, unless GVHD occurred; and mycophenolate mofetil 15 mg/kg orally three times a day from day +5 to day +35. 5 The choice of the CNI was related to each center's policy. At Institut Paoli Calmettes, Marseille, all patients received CsA, whereas at Humanitas Clinical and Research Center, Rozzano, patients received Tacrolimus until March 2013, when the policy was changed in favor of CsA. Mesna was administered and patients were hyperhydrated to prevent Cy-induced HC. Information about supportive care is available in Supplementary Information. The conditioning regimens were classified as Thiotepa and/or Busulfan (TT/Bu) based or truly nonmyeloablative regimen (Baltimore platform). Further details of the conditioning regimens are available in Supplementary Information.
PV-HC was defined by the association of urinary symptoms, positive PV viruria and hematuria in the absence of other conditions, with negative urine tests for other pathogens. The onset of PV-HC was defined as the first day of urinary symptoms associated with hemorrhagic signs, and remission was defined as the last day of bleeding. HC presenting before the seventh day post-HSCT were excluded, as they were considered potentially related to Cy administration. Urinalysis and PCR testing for urinary BK and JC virus were performed at the onset of urinary symptoms. DNA was extracted by an automated nucleic acid platform, and quantification of BKV and JC virus was carried using real-time PCR. Any level of PV viruria was defined as positive. PV-HC was graded according to the standard criteria. 6 The cumulative incidence of PV-HC was calculated according to the FK-or CsA-based immunosuppressive regimen used; then multivariate hazard ratios of developing PV-HC were calculated through Cox regression model with the other significant variables tested as potential risk factors to develop PV-HC. Variables with a P-value o0.1 entered the multivariate model. Statistical significance was set at P = 0.05.
The median age of the study population was 53 (range: 19-73) years. The CNI administered as part of the GVHD prophylaxis was CsA in 109 (68%) patients and FK in the remaining 52 (32%) patients. Fifty (31%) conditioning regimens were defined as TT/Bu based, whereas 111 (69%) as truly nonmyeloablative. One hundred and sixteen (72%) patients underwent TBI at the dose of 200 cGy. The stem cell source was bone marrow in 83 (52%) cases and PBSCs in 78 (48%) cases. Seventy (43%) patients were given levofloxacin as part of the antimicrobial prophylaxis.
The median follow-up time of survivors was 14 (range: 2-61) months after transplantation. Ten patients developed a PV-HC at a median time of onset of day +24 post-HSCT (range between days +7 and +68). The overall cumulative incidence of PV-HC was 6.8% (95% confidence interval (CI): 3.4-11.6). The etiological agent was BKV in nine cases and JC virus in one case. PV-HC severity was grade 1 in two, grade 2 in three, grade 3 in four and grade 4 in one patient. The median peak urinary PV viral load was 4 × 10 7 (range: 3 × 10 4 -4 × 10 10 ) copies/mL. Of note, no patient experienced acute GVHD before the onset of PV-HC. Six out of the 52 patients receiving FK and 4 out of the 109 patients receiving CsA developed PV-HC. The cumulative incidence of PV-HC was 13% (95% CI: 5-24) in the FK group and 4% (95% CI: 1-9) in the CsA group (P = 0.048), as shown in Figure 1 . The treatment of PV-HC was supportive in 4 (40%) cases; 4 (40%) patients were given levofloxacin; the remaining 2 (20%) patients received levofloxacin and two or three doses of Cidofovir. All patients achieved a complete clinical response, after a median time of 14 (range: 5-49) days. At the end of the follow-up, 7 out of 10 (70%) patients were alive; the remaining 3 patients died from disease relapse, GVHD and multiple organ failure, respectively.
The variables known as risk factors for the development of PV-HC were evaluated in a Cox regression model, as shown in Table 1 . In the univariate analysis, the intensity of the conditioning regimen (P = 0.044), the patient's age (P = 0.064), the source of stem cells (P = 0.085), levofloxacin prophylaxis (P = 0.032) and the time to neutrophil engraftment (P = 0.090) were also associated with the occurrence of PV-HC; when evaluated in the final multivariate model; only the type of CNI (P = 0.031) and the intensity of conditioning regimen (P = 0.022) retained statistical significance (Table 1 ). The outcome estimates at 2 years for the entire series were: acute GVHD requiring systemic treatment, 30% (95% CI: 23-38); chronic GVHD, 16% (95% CI: 9-25); relapse incidence, 37% (95% CI: 28-47); non-relapse mortality, 27% (95% CI: 20-35); overall survival, 52% (95% CI: 43-61).
In this cohort of 161 adult patients receiving haplo HSCT with PT high-dose Cy for hematological malignancies, the use of FK and intensity of conditioning regimen were independently associated with a higher incidence of PV-HC. To our knowledge, our study represents the first report of a possible link between the use of FK as part of GVHD prophylaxis and an increased incidence of PV-HC in the HSCT setting.
Like what has been demonstrated in solid organ transplantation, 4 our results suggest a potential role played by the CNI used as part of GVHD prophylaxis in this specific context of haplo HSCT using a T-replete graft and PT-Cy. 5 As PV-HC is a common cause of morbidity and haplo HSCT are increasing all over the world, 7 we believe that present data are worthy of note, despite the limitations owing to the retrospective nature of the analysis and the limited number of PV-HC.
The reported incidence of PV-HC after haplo HSCT ranges between 0% and 75%. 8 This heterogeneity is due in part to the adoption of different criteria for the diagnosis of PV-HC and in part to the distribution of risk factors in the various study populations and to the different platforms applied. Our findings relate to the specific setting of T cell-replete haplo HSCT with PT-Cy. Recently, in a similar study, Ruggeri et al. 9 reported a cumulative incidence of PV-HC at 180 days of 62% and the factors associated with HC were second transplant and CMV reactivation. Different from our study, 76% of patients received antithymoglobulin serum during conditioning regimen, and this may explain the higher rate compared with our study. 9 Our results may be explained by the different molecular mechanisms of the two CNIs: indeed, as it has been demonstrated in vitro in primary human tubular epithelial cells, CsA could exert an inhibitory activity on PV replication, whereas FK would promote PV replication via FK-binding protein 12, therefore increasing the risk of PV-HC occurrence following HSCT. [10] [11] [12] The CsA target level may influence the risk of developing PV-HC after transplant by modifying the immunosuppression level and a study on the possible association between the CsA target level and the risk of PV-HC in the haplo HSCT setting may help to clarify this point. Moreover, the administration of a lower intensity of the conditioning regimen favors a greater retention of recipient's immunity early after HSCT and promotes a gradual adaptation of the immune system to PVs. 2 As an indirect confirmation, Solomon et al. 13 found a 75% rate of PV-HC in the presence of FK and after myeloablative conditioning, which is probably linked to a greater cytotoxicity on the urothelium.
In conclusion, the type of CNI and the intensity of conditioning regimen significantly affected the risk of PV-HC in this series of 161 adult patients receiving T cell-replete haplo HSCT with PT-Cy. The present results may help clinicians in defining the best prophylactic approaches as well as monitoring strategies, Abbreviations: BM = bone marrow; Bu = busulfan; CI = confidence interval; CsA = cyclosporine A; HR = hazard ratio; HSCT = hematopoietic stem cell transplantation; NS = not statistically significant; PV-HC = PV-associated post-HSCT HC; TT = thiotepa. The threshold to be evaluated by multivariate analysis was P = 0.1. Variables with NS factors in the multivariate analysis were excluded from the final model. Statistically significant values are in bold.
especially for those patients at higher risk of developing PV-HC after haplo transplant.
